A new wave of medicines has emerged in recent years, to supplement the established small and large molecule platforms. These complex medicines will become as important as traditional small molecule drugs in the coming years, with market values of hundreds of billions of pounds.
We partnered with CPI to engage stakeholders across the UK, through surveys and interviews, to develop an understanding of the complex medicines landscape, the challenges encountered by those working in this area, and to develop clear recommendations to support the sector for national growth and impact in this space.
“From an investor’s perspective, this field provides an avenue for even generalist investors to also capitalise on cutting-edge science. The complex medicines train is just leaving the station, so the journey is far from over – but the savviest investors will have secured the first-class tickets.” – Dr Claire Brown, Interim Chief Investment Officer (Oxford Science Innovation)
Download our State of the Discovery Nation 2021 report to get a more in-depth look into complex medicines.
Accelerating analgesic development through human-specific in vitro systems
Preclinical to clinical, building a translational link between in vitro and in vivo models of neuroinflammation for drug discovery.
